Seaside will move an autism drug into late-stage development

09/9/2010 | American City Business Journals

Seaside Therapeutics will proceed with late-stage trials of drug candidate STX209 for fragile X syndrome and autism spectrum disorder. The move comes after a second Phase II study showed that the treatment significantly improved symptoms of autism spectrum disorder in patients ages 6 to 17. The first trial was a placebo-controlled study of fragile X syndrome patients.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC